Abstract
The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.
Original language | English (US) |
---|---|
Pages (from-to) | E270-E272 |
Journal | American journal of therapeutics |
Volume | 25 |
Issue number | 2 |
DOIs | |
State | Published - Mar 1 2018 |
Bibliographical note
Publisher Copyright:© 2017 Wolters Kluwer Health, Inc. All rights reserved.
Keywords
- Bortezomib
- Immune-mediated thrombocytopenia purpura